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Scompared with cisplatin alone for mesothelioma improves
survival,30 we are currently studying a combination regimen
using this alternative. A phase I trial of HIOC with cisplatin
at its established MTD in combination with dose-escalated
gemcitabine after EPP or P/D, as appropriate, is currently
open at our institution (http://www.clinicaltrials.gov/ct2/
results?term¼tilleman). We are using gemcitabine com-
bined with cisplatin rather than pemetrexed initially because
it has been safely provided as intracavitary therapy in the
abdomen for ovarian cancer.
The present prospective phase II study establishes that
HIOC after EPP can be performed with acceptable morbidity
and mortality compared with previous studies that report
similar numbers.7,25,26 Cytoprotection with amifostine and
sodium thiosulfate merits further investigation for control
of cisplatin-related renal toxicity.
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Discussion
Dr ValerieW. Rusch (New York, NY). Thank you for asking me
to discuss this excellent article, which was extremely well pre-
sented.
During the past 20 years, there have been significant improve-
ments in the management of this disease, including a better under-
standing of its biology, improved methods and staging, decreases in
operative mortality, and the development of better radiation and
chemotherapy treatments. However, MPM is still refractory to stan-
dard treatment approaches and is usually fatal. Therefore novel
approaches to the treatment of this disease are clearly needed,
and in this regard I congratulate your group for innovative work
testing the application of hyperthermic intracavitary chemotherapy
to patients undergoing resection for MPM.
Intracavitary chemotherapy in conjunction with maximal cytor-
eductive surgery has become a standard treatment option for peri-
toneal-based malignancies, such as metastatic ovarian cancer and
primary peritoneal mesothelioma. The mortality and morbidity of
this treatment strategy are clearly linked to the expertise of thergery c August 2009
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Ssurgical and anesthetic team because the operations are usually
long and associated with high need for intravenous fluids and trans-
fusions. Previous studies for peritoneal disease have shown that
nonplatinum chemotherapy regimens appear to be associated
with fewer serious adverse events, such as renal toxicity. Because
intracavitary chemotherapy in either the pleural or peritoneal cavi-
ties penetrates to a depth of only about 5 mm, successful treatment
with this modality depends on the amount of tumor remaining after
cytoreductive surgery. Moreover, multiple cycles of intraperitoneal
chemotherapy or the addition of systemic therapy appear to play
a role in achieving better long-term disease control.
Other studies have tested the application of intracavitary chemo-
therapy to malignant pleural effusions and to metastatic thymoma.
In the early 1990s at Sloan–Kettering, we performed a phase II trial
in patients with MPMwho received intrapleural cisplatin and mito-
mycin without hyperthermia immediately after pleurectomy and
decortication. Systemic chemotherapy was added postoperatively.
Briefly, this trial showed that intrapleural chemotherapy can be ad-
ministered safely by using standard measures of intensive hydration
without renal protective agents but that the treatment approach was
relatively ineffective in preventing local tumor recurrence. Impor-
tantly, pharmacokinetic studies from that trial showed that very
high chemotherapy drug levels can be achieved intrapleurally but
that systemic absorption was rapid, with peak plasma levels being
reached within 1 hour, emphasizing the importance of protecting
renal function when administering cisplatin intrapleurally.
The present study by the Brigham group and the 2 previous trials
that they performed extend this experience with intrapleural che-
motherapy in several ways: by adding hyperthermia, which is
thought to enhance chemotherapy activity; by adding sodium thio-
sulfate and amifostine as renal protective agents to enable the use of
very high-dose chemotherapy; and by perfusing both the pleural
and peritoneal cavities in the hope of decreasing the risk of perito-
neal, as well as pleural, disease recurrence.
As shown here, the combined modality treatment was feasible
with a 4% in-hospital mortality but was associated with significant
morbidity. In the manuscript draft that I received, there was an
overall 14% risk of significant renal dysfunction and a 13% risk
of deep venous thrombosis and pulmonary embolus, a problem
that has also been noted with intraperitoneal chemotherapy.
Unfortunately, the median survivals are very similar to those ob-
served in trials of other, simpler treatment strategies, such as resec-
tion and radiation, and appear less favorable than the median
survivals in recently reported European and North American trials
of induction systemic therapy followed by EPP and adjuvant hemi-
thoracic radiation. Moreover, recurrence in the ipsilateral thorax
and peritoneum with this approach remains quite frequent.
Therefore at this point, one could ask whether the treatment
strategy used in this trial is ready for export into more routine clin-
ical practice. I think the answer is no, given the substantial risk of
treatment-related morbidity and mortality and median survivals
that do not suggest superiority over other treatment regimens.The Journal of Thoracic andHowever, I hope that these provocative results will lead the Brig-
ham group and other investigators to additional trials that will
define the ultimate role of this approach in the treatment of this dif-
ficult disease. I would encourage them to consider pharmacoki-
netic studies that might identify ways to minimize renal toxicity.
In this regard I would like to ask you 3 questions.
First, does the reduction of operative mortality from 11% in the
first study reported by your group in the Journal of Clinical Oncol-
ogy in which patients underwent pleurectomy and decortication to
4% in this trial that used EPP merely reflect a 10-year difference in
the patients’ median age between those 2 studies, or is it related to
other factors?
Dr Tilleman. Dr Rusch, thank you very much for the summary
and the review comments.
There is a difference between those 2 studies, the one reported in
the Journal of Clinical Oncology and the one we are presenting
right now. The difference can be attributed to several things. One
of them is, as you pointed out, the difference in patient age (71 years
for the P/D strategy vs 60 years for the current EPP strategy).
I would like to emphasize that in the Journal of Clinical Oncology
we have reported P/D in patients who were not eligible for EPP
because of high risk; hence a higher mortality might be expected.
The last contribution might be due to an improvement in the peri-
operative critical care during the years, and there is a learning curve
here.
Dr Rusch. In a previous phase I trial you found that amifostine
did not provide adequate protection against renal toxicity. Can you
explain why it was added to thiosulfate in this study and why it
appears that it might work?
Dr Tilleman. You are correct, the phase I study in which we
applied only amifostine did not show significant renal protection;
however, in this study we have shown that thiosulfate and amifos-
tine administered together have created this change. In this study
there were 9 patients who had renal toxicities with thiosulfate,
and only a single patient had renal toxicity after the administration
of amifostine in addition to thiosulfate. Therefore there might be
a synergistic cytoprotective reaction, but as you quoted, amifostine
alone did not provide such renal protection.
DrRusch. I will close with a third question. Given the frequency
of intra-abdominal recurrence in this study and the well-known risk
of tumor implantation by mesothelioma, have you reconsidered
your strategy of perfusing both the chest and the abdomen?
Dr Tilleman. We reported in 1997 local recurrence within the
ipsilateral hemithorax and by direct extension into the abdomen.14
Adding intraoperative intracavitary chemotherapy reduced local re-
currences from 67% to 34%, yet the abdominal recurrences did not
change, even after adding intracavitary chemotherapy (Table 4).
Baldini and coworkers’ work14 showed the same abdominal
recurrence rate (50% recurrence). Therefore, yes, a more rigorous
treatment might be needed, including washing first the abdomen,
omentectomy, and administration of systemic chemotherapy. All
might reduce recurrences in the abdomen.Cardiovascular Surgery c Volume 138, Number 2 411
